Urinary concentration of phthalates and bisphenol A during minipuberty is associated with reproductive hormone

Matilde Lærkeholm Müller1, Alexander Siegfried Busch2, Marie Lindhardt Ljubicic1

  • 1Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Insights

Exposure to endocrine disrupting chemicals like DnBP, DEHP, and BPA during infant minipuberty may alter male reproductive hormone levels. This critical developmental window is sensitive to chemical exposures, impacting hormonal balance in infant boys.

Area of Science:

  • Endocrinology
  • Environmental Health
  • Pediatrics

Background:

  • Minipuberty, a transient postnatal activation of the hypothalamic-pituitary-gonadal axis, is a crucial developmental stage highly susceptible to endocrine disruption.
  • Investigating the impact of environmental chemical exposures on male reproductive hormones during this sensitive period is vital for understanding long-term health implications.

Purpose of the Study:

  • To explore the associations between urinary concentrations of potential endocrine disrupting chemicals (EDCs) and serum reproductive hormone levels in infant boys during minipuberty.
  • To identify specific EDCs that may affect male reproductive hormone concentrations during this critical developmental window.

Main Methods:

  • Analysis of serum reproductive hormones and urinary EDC metabolites in 36 infant boys from the COPENHAGEN Minipuberty Study.
  • Measurement of urinary concentrations of 39 non-persisting chemicals, including phthalates and phenolic compounds, using LC-MS/MS.
  • Statistical analysis using linear regression to assess associations between urinary EDC metabolite concentrations (in tertiles) and hormone outcomes (age- and sex-specific SD-scores).

Main Results:

  • Urinary di-n-butyl phthalate (DnBP) metabolite concentrations were associated with altered luteinizing hormone (LH), anti-Müllerian hormone (AMH), testosterone/LH ratio, and insulin-like peptide 3 (INSL3) levels.
  • Urinary di-(2-ethylhexyl) phthalate (DEHP) metabolite concentrations were linked to higher LH and AMH levels.
  • Higher urinary bisphenol A (BPA) concentrations were associated with significantly higher AMH and lower dehydroepiandrosterone sulfate (DHEAS) levels.

Conclusions:

  • Exposure to EU-regulated chemicals such as DnBP, DEHP, and BPA during infant minipuberty may modify male reproductive hormone concentrations.
  • Minipuberty represents a critical developmental window sensitive to endocrine disruption by environmental chemicals.
  • These findings highlight the potential risks of EDC exposure on male reproductive development during early life.
Abstract

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
484
Psychosexual Stages of Personality: Phallic01:12

Psychosexual Stages of Personality: Phallic

The third stage of psychosexual development proposed by Freud is the phallic stage, occurring between the ages of 3 and 6. During this period, children become aware of their bodies and the differences between males and females. The erogenous zone in this stage is the genitals, and conflicts arise as children develop desires toward the opposite-sex parent. Boys experience the Oedipus complex, where they desire their mother and view their father as a rival. This leads to castration anxiety, the...
741
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.6K